Mortality

Talk Ten Tuesdays 500th Episode - Q&A with Chuck Buck

Retrieved on: 
Tuesday, March 15, 2022

So, we started ICD10 Monitor in 2011 and began the broadcast , "Talk Ten Tuesdays," reporting on ICD-10, so that's the genesis of Talk Ten Tuesday.

Key Points: 
  • So, we started ICD10 Monitor in 2011 and began the broadcast , "Talk Ten Tuesdays," reporting on ICD-10, so that's the genesis of Talk Ten Tuesday.
  • Chuck: The biggest challenge and I don't think I'm alone in this is trying to understand the anatomy involved.
  • I can talk about body parts at a cocktail party now for about five minutes and sound pretty authoritative.
  • Chuck: That's a subject we talk about frequently on ICD10 Monitor and Talk Ten Tuesday.

RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea

Retrieved on: 
Tuesday, March 15, 2022

TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.

Key Points: 
  • TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.
  • Kukbo will receive the exclusive rights to commercialize opaganib in South Korea for COVID-19.
  • Together with our partner, Kukbo, we are working hard to bring opaganib to Korean patients in need of new COVID-19 therapeutic options."
  • "With the data supporting opaganib for COVID-19, and the expanded partnership with RedHill, Kukbo is determined to work with local regulators with the aim of bringing opaganib to South Korean patients, as soon as possible."

Worldwide Intranasal Therapeutics and Drug Delivery Systems Market Distribution to 2035 - Industry Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 15, 2022

The "Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication, Type of Molecule and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication, Type of Molecule and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape and the likely future potential associated with the intranasal therapeutics and drug delivery systems market.
  • Who are the key players engaged in the development of intranasal therapeutics and drug delivery systems?
  • What are the anticipated future trends related to intranasal therapeutics and drug delivery systems?

National Quality Initiatives Amplify Health Systems’ Focus on Effective Glycemic Management as Glytec Fortifies Industry Leadership Position

Retrieved on: 
Tuesday, March 15, 2022

As organizations place a growing emphasis on patient safety and payments shift to a more value-based model, hospitals and health systems are steadily increasing their focus on ensuring efficient glycemic management.

Key Points: 
  • As organizations place a growing emphasis on patient safety and payments shift to a more value-based model, hospitals and health systems are steadily increasing their focus on ensuring efficient glycemic management.
  • The CMS national quality initiatives have indicated that poor glycemic management has become too pervasive to ignore and hospitals must evolve.
  • Visit Booth #4135 to learn more about Glytec and the impact that insulin management software can have on health systems.
  • Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care.

LimFlow Completes Enrollment in PROMISE II U.S. Pivotal Trial of Breakthrough Device Designed to Prevent Amputations in No-Option Patients With Chronic Limb-Threatening Ischemia

Retrieved on: 
Tuesday, March 15, 2022

The LimFlow System is designed to reestablish arterialization in deep veins for patients who have exhausted other methods and face major amputation of their lower limbs.

Key Points: 
  • The LimFlow System is designed to reestablish arterialization in deep veins for patients who have exhausted other methods and face major amputation of their lower limbs.
  • The no-option patients treated in PROMISE II were determined by an independent physician committee to be no longer eligible for conventional endovascular or surgical therapy to treat CLTI.
  • The PROMISE II investigators are very encouraged by our experience using the LimFlow System to treat CLTI patients with no other options.
  • LimFlow also announced completion of enrollment in the CLariTI study of approximately 200 high-risk and no-option CLTI patients.

New Alzheimer's Association Report Finds Doctors and the Public Face Challenges in Understanding and Distinguishing Early Alzheimer's Development from 'Normal Aging'

Retrieved on: 
Tuesday, March 15, 2022

CHICAGO, March 15, 2022 /PRNewswire/ -- The Alzheimer's Association 2022 Alzheimer's Disease Facts and Figures report unearthed new insights related to challenges both doctors and the American public face in understanding and diagnosing mild cognitive impairment (MCI), which is characterized by subtle changes in memory and thinking. It is estimated 10% to 15% of individuals with MCI go on to develop dementia each year. And as the size of the U.S. population age 65 and older continues to grow (from 58 million in 2021 to 88 million by 2050), so too will the number and proportion of Americans with Alzheimer's or other dementias given increased risk of dementia with advancing age.

Key Points: 
  • About one-third of people with MCI due to Alzheimer's disease develop Alzheimer's dementia within five years.
  • When MCI due to Alzheimer's disease is described, almost half of respondents(42%) express worry about developing it in the future.
  • Additional findings illuminate why individuals exhibiting MCI symptoms are reluctant to discuss them with their doctors, who face persistent challenges in diagnosis of their patients.
  • The report will also appear in the April 2022 issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

Retrieved on: 
Tuesday, March 15, 2022

The study is an international, randomized double-blind, placebo-controlled study designed to assess the efficacy and safety of istaroxime and to support an intended pathway for the development in early cardiogenic shock.

Key Points: 
  • The study is an international, randomized double-blind, placebo-controlled study designed to assess the efficacy and safety of istaroxime and to support an intended pathway for the development in early cardiogenic shock.
  • The study has enrolled 60 Society for Cardiovascular Angiography & Interventions (SCAI) class B early cardiogenic shock patients with severe heart failure (30 assigned to istaroxime and 30 assigned to placebo) and systolic blood pressures (SBP) between 75-90 mmHg.
  • We are very pleased to have completed enrollment in the study of istaroxime in early cardiogenic shock due to heart failure.
  • Market research revealed 99% of 100 U.S.-based clinical cardiologists interviewed who treat cardiogenic shock patients responded that new drug innovation to treat SCAI class B cardiogenic shock patients is highly needed.

DGAP-News: Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

Retrieved on: 
Tuesday, March 15, 2022

Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

Key Points: 
  • Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
    The issuer is solely responsible for the content of this announcement.
  • Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
    Hennigsdorf/Berlin (Germany), 15 March, 2022 - Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. Richard Jones as Chief Executive Officer of Adrenomed, effective today.
  • "I am delighted to welcome Dr. Richard Jones as the new CEO of Adrenomed.
  • Dr. Richard Jones, CEO of Adrenomed, said: "I am excited to be joining Adrenomed at a pivotal phase of the Company's evolution.

DGAP-News: Proenkephalin (penKid) sheds light on the diagnostic blind spots in assessing acute kidney injury in children

Retrieved on: 
Tuesday, March 15, 2022

For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.

Key Points: 
  • For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.
  • AKI is mostly diagnosed too late for successful intervention which leads to steep mortality rates and chronic kidney disease (1,2).
  • Bennett MR, Nehus E, Haffner C, Ma Q, Devarajan P. Pediatric reference ranges for acute kidney injury biomarkers.
  • Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock.

Cardiawave Announces the Success of Its Clinical Trial to Treat Aortic Stenosis Using VALVOSOFT®, Its Disruptive, Non-Invasive, Ultrasound Treatment

Retrieved on: 
Monday, March 14, 2022

VALVOSOFT provided a sustained repair to the aortic vavlve for up to 12 months post treatment.

Key Points: 
  • VALVOSOFT provided a sustained repair to the aortic vavlve for up to 12 months post treatment.
  • This represents a new treatment solution for aortic stenosis, over and above aortic valve replacement from which only a small minority of patients can benefit.
  • This non-invasive treatment of aortic stenosis combines therapeutic ultrasound, robotics and ultrasound imaging.
  • Aortic stenosis is a degenerative and potentially life-threatening condition, caused by calcium buildup which prevents the aortic valve from fully opening.